Clinical Trials | June 23, 2026
Pfizer lung cancer drug misses key survival goal in Phase 3 trial
The company said the safety profile remained consistent with earlier studies and was considered manageable
The company said the safety profile remained consistent with earlier studies and was considered manageable
The regulatory decision follows promising results from RIVER-81
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
This marks one of the most closely watched oncology readouts at this year’s medical congress
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
